局部晚期非小细胞肺癌大分割质子治疗同步化疗的1期试验
该多中心1期试验评估了II/III期非小细胞肺癌患者接受大分割质子治疗同步化疗的安全性,采用5+2剂量递增方案,分4个剂量组(2.5、3.0、3.53、4.0 GyRBE/次,总剂量60 GyRBE)。因入组缓慢提前关闭,18例患者可评估,未确定最大耐受剂量;3.53 GyRBE组7例中发生2例严重不良事件,但经外部专家评审均归因于化疗。结论认为2.5-3.53 GyRBE/次同步化疗毒性可接受。
要点
- 大分割质子治疗2.5-3.53 GyRBE/次同步化疗耐受性可接受。
- 3.53 GyRBE组2例SAE经评审归因于化疗而非放疗。
- 研究因入组慢提前关闭,未确定最大耐受剂量。
核心结论
- 大分割质子治疗2.5至3.53 GyRBE/次、总剂量60 GyRBE同步化疗具有可接受的毒性特征。
- 未确定最大耐受剂量,建议进一步开展2期临床试验探索该方案。
研究设计与样本
- 多中心1期临床试验,2013年至2018年入组新诊断II或III期非小细胞肺癌患者。
- 采用5+2剂量递增方案,设4个剂量组:2.5 GyRBE/次至60 GyRBE、3.0 GyRBE/次至60 GyRBE、3.53 GyRBE/次至60.01 GyRBE、4.0 GyRBE/次至60 GyRBE。
- 剂量组可耐受定义为5例入组患者中90天内无放疗相关严重不良事件,或7例中仅1例发生。
- 心脏、臂丛和脊髓的剂量约束在高分次剂量下更保守。
主要发现
- 研究因入组缓慢和NRG 1308竞争入组提前关闭,未达到计划入组数。
- 共18例患者接受治疗:第1和第2组各5例,第3组7例,第4组1例。
- 3.53 GyRBE/次组7例中发生2例严重不良事件,经外部专家评审均归因于化疗、与放疗无关。
关键数值与推荐
- 剂量组可耐受标准:5例中0例或7例中1例发生放疗相关严重不良事件(90天内)。
- 3.53 GyRBE/次组7例中2例严重不良事件,但归因于化疗。
临床怎么用
- 对于局部晚期非小细胞肺癌,大分割质子治疗2.5-3.53 GyRBE/次同步化疗可作为毒性可接受的探索性方案。
- 需在2期临床试验中进一步验证该方案的疗效和安全性。
局限性
- 研究因入组缓慢提前关闭,样本量小(18例),未确定最大耐受剂量。
- 第4组仅1例患者,数据有限。
- 严重不良事件归因于化疗基于外部专家评审,可能存在归因偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report the safety data from the first multicenter phase 1 trial investigating the use of hypofractionated proton therapy with concurrent chemotherapy for patients with stage II or III non-small cell lung cancer. METHODS AND MATERIALS: From 2013 through 2018, patients with newly diagnosed stage II or III non-small cell lung cancer were enrolled in a multicenter phase 1 clinical trial evaluating concurrent chemotherapy with increasing dose-per-fraction proton therapy. This was a stepwise 5 + 2 dose-intensification protocol with the following dose arms: (1) 2.5 GyRBE per fraction to 60 GyRBE; (2) 3.0 GyRBE per fraction to 60 GyRBE; (3) 3.53 GyRBE per fraction to 60.01 GyRBE; and (4) 4.0 GyRBE per fraction to 60 GyRBE. A dose arm was considered tolerable if no radiation therapy-attributable severe adverse event (SAE) occurred within 90 days of treatment among 5 patients enrolled on the arm or if 1 SAE occurred among 7 patients enrolled. Dose constraints to the heart, brachial plexus, and spinal cord were more conservative at higher doses per fraction. RESULTS: The study closed early because of slow accrual and competing enrollment in NRG 1308 before accrual was met, with no maximum tolerated dose identified. Eighteen patients were treated, including 5 patients on arms 1 and 2, 7 patients on arm 3, and 1 patient on arm 4. Two SAEs occurred among 7 patients treated at 3.53 GyRBE per fraction; however, per outside expert review, both were attributed to chemotherapy and unrelated to radiation therapy. CONCLUSIONS: Hypofractionated proton therapy delivered at 2.5 to 3.53 GyRBE per fraction to a dose of 60 GyRBE with concurrent chemotherapy has an acceptable toxicity profile. Further exploration of this regimen is warranted on a phase 2 clinical trial.
引用
- Hoppe BS, Nichols RC, Flampouri S, et al. Hypofractionated Proton Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial from the University of Florida and Proton Collaborative Group. Int J Radiat Oncol Biol Phys. 2020. PMID: 32251754. doi:10.1016/j.ijrobp.2020.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。